Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat

Brain Research Bulletin

Volumn 81, Issue 6, 2010, Pages 543-548

  Walsh, Sinéad ^a   Mnich, Katarzyna ^a   Mackie, Ken ^b   Gorman, Adrienne M ^a   Finn, David P ^a   Dowd, Eilís ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b INDIANA UNIVERSITY   (United States)

Author keywords

6 Hydroxydopamine; CB1 receptor; Endocannabinoid system; Parkinson's disease; Substantia nigra

Indexed keywords

CANNABINOID 1 RECEPTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; ADRENERGIC RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION; GENETICS; MEDIAL FOREBRAIN BUNDLE; METABOLISM; NERVE CELL; NERVE DEGENERATION; NERVE FIBER; ORGAN SIZE; PARKINSONISM; PATHOLOGY; RANDOMIZATION; SUBSTANTIA NIGRA; TIME;

ADRENERGIC AGENTS; ANIMALS; AXONS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE EXPRESSION; MALE; MEDIAL FOREBRAIN BUNDLE; NERVE DEGENERATION; NEURONS; ORGAN SIZE; OXIDOPAMINE; PARKINSON DISEASE; PARKINSONIAN DISORDERS; RANDOM ALLOCATION; RATS; RECEPTOR, CANNABINOID, CB1; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 76749165654     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2010.01.009     Document Type: Article

References (48)

1. Benito C., Nunez E., Tolon R.M., Carrier E.J., Rabano A., Hillard C.J., and Romero J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23 (2003) 11136-11141
2. Birkmayer W., and Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in Parkinsonism. Parkinsonism Relat. Disord. 4 (1998) 59-60
3. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., and Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 256 (1999) 377-380
4. Brotchie J.M. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr. Opin. Pharmacol. 3 (2003) 54-61
5. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., and Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 15 (2002) 991-998
6. Cotzias G.C., Papavasiliou P.S., and Gellene R. Modification of Parkinsonism-chronic treatment with l-dopa. N. Engl. J. Med. 280 (1969) 337-345
7. Crawley J.N., Corwin R.L., Robinson J.K., Felder C.C., Devane W.A., and Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46 (1993) 967-972
8. Depino A.M., Earl C., Kaczmarczyk E., Ferrari C., Besedovsky H., del Rey A., Pitossi F.J., and Oertel W.H. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. 18 (2003) 2731-2742
9. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34 (1988) 605-613
10. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., and Brotchie J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14 (2000) 1432-1438
11. Dowd E., and Dunnett S.B. Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats. Behav. Brain Res. 159 (2005) 153-161
12. Dowd E., and Dunnett S.B. Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in rats using a lateralised nose-poking task with low stimulus-response compatibility. Behav. Brain Res. 165 (2005) 181-186
13. Dowd E., Monville C., Torres E.M., and Dunnett S.B. The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res. Bull. 68 (2005) 24-30
14. Egertova M., and Elphick M.R. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J. Comp. Neurol. 422 (2000) 159-171
15. Ehringer H., and Hornykiewicz O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.]. Klin. Wochenschr. 38 (1960) 1236-1239
16. Forno L.S. Neuropathologic features of Parkinson's, Huntington's, and Alzheimer's diseases. Ann. N. Y. Acad. Sci. 648 (1992) 6-16
17. Garcia-Arencibia M., Gonzalez S., de Lago E., Ramos J.A., Mechoulam R., and Fernandez-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 1134 (2007) 162-170
18. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., and Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2 (1999) 358-363
19. Glass M., Faull R.L., and Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56 (1993) 523-527
20. Grealish S., Xie L., Kelly M., and Dowd E. Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat. Brain Res. Bull. (2008)
21. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agro A., and Maccarrone M. Experimental Parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22 (2002) 6900-6907
22. Herkenham M., Lynn A.B., de Costa B.R., and Richfield E.K. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547 (1991) 267-274
23. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 1932-1936
24. Hohmann A.G., and Herkenham M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 37 (2000) 71-80
25. Hurley M.J., Mash D.C., and Jenner P. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J. Neural Transm. 110 (2003) 1279-1288
26. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
27. Kreitzer A.C., and Malenka R.C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445 (2007) 643-647
28. Lastres-Becker I., Cebeira M., de Ceballos M.L., Zeng B.Y., Jenner P., Ramos J.A., and Fernandez-Ruiz J.J. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 14 (2001) 1827-1832
29. Mailleux P., and Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48 (1992) 655-668
30. Mailleux P., and Vanderhaeghen J.J. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J. Neurochem. 61 (1993) 1705-1712
31. Matsuda L.A., Bonner T.I., and Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 327 (1993) 535-550
32. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
33. Matyas F., Yanovsky Y., Mackie K., Kelsch W., Misgeld U., and Freund T.F. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 137 (2006) 337-361
34. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
35. Moldrich G., and Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 21 (2000) 1735-1742
36. Pettit D.A., Harrison M.P., Olson J.M., Spencer R.F., and Cabral G.A. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J. Neurosci. Res. 51 (1998) 391-402
37. Pisani A., Fezza F., Galati S., Battista N., Napolitano S., Finazzi-Agro A., Bernardi G., Brusa L., Pierantozzi M., Stanzione P., and Maccarrone M. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 57 (2005) 777-779
38. Price D.A., Martinez A.A., Seillier A., Koek W., Acosta Y., Fernandez E., Strong R., Lutz B., Marsicano G., Roberts J.L., and Giuffrida A. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur. J. Neurosci. 29 (2009) 2177-2186
39. Ramirez B.G., Blazquez C., Gomez del Pulgar T., Guzman M., de M.L., and Ceballos. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 (2005) 1904-1913
40. Romero J., Berrendero F., Perez-Rosado A., Manzanares J., Rojo A., Fernandez-Ruiz J.J., de Yebenes J.G., and Ramos J.A. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci. 66 (2000) 485-494
41. Romero J., Garcia L., Cebeira M., Zadrozny D., Fernandez-Ruiz J.J., and Ramos J.A. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sci. 56 (1995) 2033-2040
42. Sanudo-Pena M.C., Tsou K., and Walker J.M. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65 (1999) 703-713
43. Sanudo-Pena M.C., and Walker J.M. A novel neurotransmitter system involved in the control of motor behavior by the basal ganglia. Ann. N. Y. Acad. Sci. 860 (1998) 475-479
44. Schwarting R.K., and Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 (1996) 275-331
45. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
46. Wallmichrath I., and Szabo B. Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 113 (2002) 671-682
47. Weinstein A., Brickner O., Lerman H., Greemland M., Bloch M., Lester H., Chisin R., Sarne Y., Mechoulam R., Bar-Hamburger R., Freedman N., and Even-Sapir E. A study investigating the acute dose-response effects of 13 mg and 17 mg Delta 9-tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. J. Psychopharmacol. 22 (2008) 441-451
48. Zeng B.Y., Dass B., Owen A., Rose S., Cannizzaro C., Tel B.C., and Jenner P. Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci. Lett. 276 (1999) 71-74